Evaluation of degarelix in the management of prostate cancer. - Wikidata - awgldk - TriplyDB

Evaluation of degarelix in the management of prostate cancer.

Evaluation of degarelix in the management of prostate cancer.

http://www.wikidata.org/entity/Q34417797

about

In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth GPCRs and cancer Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.Subcapsular orchiectomy in the primary therapy of patients with bone metastasis in advanced prostate cancer: an anachronistic intervention?Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.Redefining hormone sensitive disease in advanced prostate cancer.

P2860

Q28545022-CC0F1A6D-8951-4228-9B86-8CD822DC70E1 Q33828719-D87BC72B-1610-49DD-A290-063B1FDA84BD Q34637448-C3FA254A-BD50-45F7-9CE1-1EF499B65FC3 Q38414862-D7895B32-F4A8-47B2-A08D-9B3B0C4BF78D Q38539324-7615F91A-ABFC-44A4-9651-BF1A74100AA1 Q38844498-63C1E076-C37B-4C35-A93A-707A1175DB74 Q40018470-BFAA39A3-672F-42DB-8A38-77531E483BA5 Q42593799-B201A834-86CE-4625-B778-DCA71C4A29B5

P2860

Evaluation of degarelix in the management of prostate cancer.

http://www.wikidata.org/entity/Q34417797

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evaluation of degarelix in the management of prostate cancer.

@ast

Evaluation of degarelix in the management of prostate cancer.

@en

Evaluation of degarelix in the management of prostate cancer.

@nl

type

label

Evaluation of degarelix in the management of prostate cancer.

@ast

Evaluation of degarelix in the management of prostate cancer.

@en

Evaluation of degarelix in the management of prostate cancer.

@nl

prefLabel

Evaluation of degarelix in the management of prostate cancer.

@ast

Evaluation of degarelix in the management of prostate cancer.

@en

Evaluation of degarelix in the management of prostate cancer.

@nl

P1433

Q34417797-C19C51BC-DFD6-4C5B-B9C3-1F9D4A8AD0C6

P1476

Q34417797-5B680F2C-5642-48E6-AA7B-286B0895CF73

P2093

Q34417797-0A64F183-F9B9-4B36-B160-DC95C6E94CBE

P2860

Q34417797-0CEDCBE9-62C2-449D-9680-46D9AEB130BA

Q34417797-1853FEE0-820D-4D8E-9343-1924ED042D54

Q34417797-1DCA52AA-2D7D-45F0-B2AD-1F3A2D395936

Q34417797-1F2F0A0C-4A8A-48B7-ACC9-229F4ADD6FC3

Q34417797-2485CE16-7D4F-492F-8F6A-4A7AF61DD8AB

Q34417797-2642D256-B9F8-4700-9A08-71C69E638FFF

Q34417797-30880A2C-1DC5-4A27-9633-485C20C167CA

Q34417797-30DD1FA7-37CE-4580-A801-5F249B87B963

Q34417797-34CF0EF7-7577-406F-9543-8B70C36FDD9F

Q34417797-39508151-33F5-4BB8-A4A6-BFD19F1AFD13

P304

Q34417797-32E9A224-6922-4EDD-98B0-2FB3E8652745

P31

Q34417797-3f5a826a-0543-4013-9d16-409604c0c7f6

Q34417797-AF06357C-8D0A-404B-94D4-370BD88E6934

P356

Q34417797-D1BAE00E-E56D-4AA6-8225-669C8CDB4072

P407

Q34417797-0D3E7162-96B6-414F-B62E-3325B3D26876

P478

Q34417797-7B01938C-1AB3-4EF2-930A-748FD81A96CF

P577

Q34417797-4438329B-91A0-49F8-A1B6-DFFA9D7B59D8

P698

Q34417797-EAB3E236-7C2C-4893-BC71-85C4BA0811A3

P932

Q34417797-AD591D46-728C-44ED-A24A-60887064809E

P356

P1433

Cancer Management and Research

P1476

Evaluation of degarelix in the management of prostate cancer.

@en

P2093

Hendrik Van Poppel

http://www.w3.org/2001/XMLSchema#string

P2860

Androgen deprivation therapy in the treatment of advanced prostate cancer

Management of complications of prostate cancer treatment.

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

[EAU guidelines on prostate cancer].

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

Drug evaluation: Degarelix--a potential new therapy for prostate cancer.

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.

P304

39-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S8841

http://www.w3.org/2001/XMLSchema#string

P407

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21188095

http://www.w3.org/2001/XMLSchema#string

P932

3004563

http://www.w3.org/2001/XMLSchema#string